Becton, Dickinson and Company Stock price

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-02-29 pm EST 5-day change 1st Jan Change
235.6 USD -1.51% Intraday chart for Becton, Dickinson and Company -3.31% -3.40%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 20.31B Sales 2025 * 21.5B Capitalization 68.05B
Net income 2024 * 2.11B Net income 2025 * 2.76B EV / Sales 2024 * 3.98 x
Net Debt 2024 * 12.83B Net Debt 2025 * 10.25B EV / Sales 2025 * 3.64 x
P/E ratio 2024 *
33 x
P/E ratio 2025 *
26 x
Employees 73,000
Yield 2024 *
1.58%
Yield 2025 *
1.61%
Free-Float 77.85%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Becton, Dickinson and Company Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM
Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024 CI
Becton, Dickinson Seeks M&A CI
Transcript : Becton, Dickinson and Company - Special Call
Becton, Dickinson Collaborating With Camtech Health for at-Home Cervical Cancer Screening in Singapore MT
Barclays Adjusts Price Target on Becton Dickinson and Co. to $305 From $301, Maintains Overweight Rating MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021. CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday MT
Transcript : Becton, Dickinson and Company, Q1 2024 Earnings Call, Feb 01, 2024
Becton, Dickinson's Fiscal Q1 Adjusted Earnings Down, Revenue Up; 2024 Guidance Revised MT
Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q DJ
(BDX) BD (BECTON DICKINSON AND COMPANY) Sees Fiscal Year 2024 EPS Range $12.82 - $13.06 MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 Revenue $4.71B, vs. Street Est of $4.73B MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 EPS $2.68, vs. Street Est of $2.40 MT
Becton, Dickinson and Company Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
More news
1 day-1.51%
1 week-3.31%
1 month-1.37%
3 months-0.27%
6 months-15.71%
Current year-3.40%
More quotes
1 week
235.06
Extreme 235.06
246.24
1 month
234.74
Extreme 234.74
246.60
Current year
232.70
Extreme 232.7
249.89
1 year
228.62
Extreme 228.615
287.32
3 years
215.90
Extreme 215.9
287.32
5 years
197.75
Extreme 197.75
287.32
10 years
111.07
Extreme 111.07
287.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 08-12-31
Director of Finance/CFO 52 21-09-05
Chief Tech/Sci/R&D Officer 48 18-12-31
Members of the board TitleAgeSince
Director/Board Member 73 02-09-23
Director/Board Member 73 13-01-28
Director/Board Member 69 10-07-25
More insiders
Date Price Change Volume
24-02-29 235.6 -1.51% 1,812,904
24-02-28 239.2 -0.87% 829,240
24-02-27 241.2 -0.20% 919,002
24-02-26 241.7 -1.82% 939,382
24-02-23 246.2 +1.06% 992,662

Delayed Quote Nyse, February 29, 2024 at 04:00 pm EST

More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (70.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (22.2%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.3%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (56.8%), Europe/Middle East/Africa (21.4%), Asia (16.2%) and other (5.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
235.6 USD
Average target price
283.1 USD
Spread / Average Target
+20.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Becton, Dickinson and Company - Nyse
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW